News >

Sequencing Strategies, Combinations Mark Next Steps in HCC

Brandon Scalea
Published: Tuesday, Oct 23, 2018

Josep M. Llovet, MD, PhD

Josep M. Llovet, MD, PhD

The recent addition of multikinase inhibitors and immunotherapies has moved the needle in the right direction for hepatocellular carcinoma (HCC), but the next steps involve sequencing these agents and incorporating combination regimens.

According to Josep M. Llovet, MD, PhD, there are several promising approaches with checkpoint inhibitors being tested in phase III studies. For example, the frontline combination of the PD-L1 inhibitor atezolizumab (Tecentriq) and bevacizumab (Avastin) was granted a breakthrough therapy designation for patients with advanced or metastatic HCC.

A phase Ib study presented at the 2018 ESMO Congress showed that atezolizumab plus bevacizumab induced a confirmed investigator-assessed objective response rate of 32% per RECIST v1.1 criteria in patients with advanced HCC, with more than half of responders maintaining their response for at least 6 months and about one-fourth for at least 12 months.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication